Gliflozins, known as Sodium–glucose cotransporter-2 (SGLT2) inhibitors, have shown significant cardiovascular (CV) benefit in high-risk patients, particularly those with type 2 diabetes mellitus (T2DM) [1, 2], chronic kidney disease (CKD) [3–5], and heart failure (HF) across a wide range of left ventricular ejection fractions [6–10]. This evidence concerns the gene SLC5A2 and chronic kidney disease.